OpenAI 收购 Orchestra Bio，推进生命科学 Rosalind 模型与工具
OpenAI ❤️ Orchestra Bio
OpenAI 宣布收购 Orchestra Bio，后者是帮助生物制药团队协调药物开发复杂流程的平台。双方将基于 OpenAI 面向生命科学研究的 Rosalind 模型与工具继续开发，以简化这些流程并让新疗法更快到达患者手中。
推荐理由
AI 评分 60
OpenAI 收购 Orchestra Bio 以推进生命科学领域的 Rosalind 模型与工具，读者可了解其在该方向的布局。
主题
查看原帖我们已收购 Orchestra Bio，这是一个帮助生物制药团队协调药物开发复杂流程的平台。 我们将共同基于 Rosalind——我们面向生命科学研究的 AI 模型与工具——继续开发，以简化这些流程，并帮助新疗法更快惠及患者。 欢迎 @ashokaraj_ 和团队！ https://t.co/vi51OhznQn
查看原文
We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! https://t.co/vi51OhznQn
正文
OpenAI ❤️ Orchestra Bio
> OpenAI has acquired Orchestra Bio to work on Rosalind models and tools for life sciences research.
> "Orchestra Bio is a platform that helps biopharma teams coordinate the complex process of drug development."
AI advancements in life sciences are probably one of the most desired areas for many. So far, it seems like a top priority for Anthropic, OpenAI, and Google.